This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Non-small Cell Lung Cancer
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
-
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
USC Norris Cancer Center, Los Angeles, California, United States, 90033
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
UCLA Hematology Oncology, Los Angeles, California, United States, 90095
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States, 92868
UC Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817
UCSF, San Francisco, California, United States, 94115
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Yale Cancer Center, New Haven, Connecticut, United States, 06520
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Genentech, Inc.,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2029-03-06